none

A BOOSTER SHOT FOR NATIONAL ECONOMY

10-08-2017
by 
in 

A first-of-its-kind ‘fill-and-finish’ injectable medicines factory will set up shop in South Australia’s Tonsley innovation hub, after securing crucial set-up funds in an investment round.

InDaily revealed last year that biopharmaceutical company GEN1 hoped to create up to 200 new jobs and inject (no pun intended) around $650 million into the state economy over a decade with the establishment of its new operation – which would formulate base compounds into medicines to fill syringes, vials and cartridges as ready-to-use injectables – pending the establishment of a suitable site and international investment.

Both these caveats have now been met, after a funding round – with expected closing next month – raised $8 million through Australian private equity investors, local banks and the South Australian Government’s Health Industries Fund.

GEN1 Chief Financial Officer Kishen Vijayadass said the initial investment round “will support the company’s delivery of a factory in Adelaide that will benefit all Australians”.

“Adelaide has a vibrant, fast-growing life sciences community and the South Australian Government, through Health Industries SA, was very responsive to GEN1 and provided invaluable support,” he said.

The company says its planned 15,000sq m factory will be the first of its kind and scale in Australia, which currently imports injectable medicines for chronic conditions such as cancer, hypertension and diabetes.

However, the national market for injectable medication exceeds $10 billion annually and is growing by 15-20 per cent a year, according to IMS Health.

Health Industries SA CEO Marco Baccanti said GEN1 would be a boon for the state’s health system, with “the potential to save SA up to $70m a year in medication spending”.

“GEN1 will be in a great position to provide high-quality cost-effective products, and it will be doing so locally, right here in Adelaide,” he said.

In a company prospectus issued in May, GEN1 noted Australia was in the top 10 of the highest per capita healthcare spending countries in the world – and the highest in Asia.

“GEN1 is an early entrant to an untapped market, with a business model not in line with the multinationals’ strategy, and out of reach of most local manufacturers,” it said.

“GEN1 offer potential partners a low risk, low cost, quick entry to a high growth industry, with early stage cash flow, relatively fast [return on investment] and a sustainable business growth.”

Related news & editorials

  1. worker
    07.05.2021
    07.05.2021
    by      In , In , In
    A $325,000 government grant has helped regional Victoria’s largest co-packing business increase its productivity through the introduction of an innovative product line and new automated equipment. 
    The grant, from the Agriculture Workforce Plan, has also enabled the Australian Disability Enterprise... Read More
  2. Angus Taylor
    06.05.2021
    06.05.2021
    by      In
    The Australian Government has given the green light to the construction of three large hydrogen plants in Victoria and Western Australia that will be among the world’s biggest.
    More than $100 million in conditional funding has been awarded through the Australian Renewable Energy Agency’s (ARENA)... Read More
  3. Lab
    05.05.2021
    05.05.2021
    by      In , In
    Newly launched space startup Quasar Satellite Technologies is set to revolutionise space communications, using radio telescope technology developed by the CSIRO. 
    With more than 57,000 satellites set to be launched by the end of the decade, Quasar is creating a world-leading ground station service... Read More
  4. 29.04.2021
    29.04.2021
    by      In
    In memory of Mr Lapp, the founding family set up the Oskar Lapp Foundation in 1992. This provides young scientists with incentives to effectively engage them in cardiovascular research. The Oskar Lapp Research Prize, worth 12,000 Euro, is presented annually, while the Oskar Lapp Grant, which... Read More
Products
Suppliers